Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412947 | 0.88 | GNAI3 (0.40) | DRD2SIGMAR1OPRD1DRD3 | |
| SCHEMBL10284004 | 0.83 | DRD2 (0.38) | DRD2SIGMAR1MEN1KMT2AOPRD1 | |
| SCHEMBL13412945 | 0.83 | KDM4E (0.34) | MEN1KMT2A | |
| SCHEMBL18536496 | 0.82 | — | — | |
| SCHEMBL5475889 | 0.82 | ALOX15 (0.52) | SIGMAR1MEN1KMT2AKCNJ1KCNH2 | |
| SCHEMBL25725668 | 0.78 | PIK3CD (0.45) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL13412949 | 0.78 | MC4R (0.38) | KCNH2DRD3 | |
| SCHEMBL2738294 | 0.78 | DAO (0.43) | DRD2SIGMAR1OPRD1KCNH2DRD3 | |
| SCHEMBL24630463 | 0.78 | DRD2 (0.35) | DRD2SIGMAR1MEN1KMT2AOPRD1 | |
| SCHEMBL20254465 | 0.76 | DAO (0.46) | DRD2SIGMAR1OPRD1KCNH2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | IGFBP5, BMP2, HGF | DRD2 3126/4885SIGMAR1 2833/4885MEN1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.